OverviewSuggest Edit

Liquidia Technologies, a nanotechnology company, designs, develops, and manufactures engineered particles and films for applications in life and materials science sectors. It develops micro and nanoparticles for the delivery of biological and small molecule therapeutics, as well as for the development of vaccines and inhaled therapeutics in the life sciences sector. The Company also develops nano-patterned optical films for displays, lighting, photovoltaics, and related applications in the material science sector.
TypePublic
Founded2004
HQMorrisville, NC, US
Websiteliquidia.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Dec 2019)64(+2%)
Revenue (FY, 2019)$8.1 M(+199%)
Share Price (Jun 2021)$2.7(-1%)
Cybersecurity ratingAMore

Key People/Management at Liquidia

Stephen Bloch

Stephen Bloch

Chairman
Mike Kaseta

Mike Kaseta

Chief Financial Officer
Robert Lippe

Robert Lippe

Chief Operations Officer
Tushar Shah

Tushar Shah

Chief Medical Officer
Rusty Schundler

Rusty Schundler

General Counsel
Scott Moomaw

Scott Moomaw

Senior Vice President, Commercial
Show more

Liquidia Office Locations

Liquidia has an office in Morrisville
Morrisville, NC, US (HQ)
419 Davis Dr
Show all (1)

Liquidia Financials and Metrics

Liquidia Revenue

Embed Graph
View revenue for all periods
Liquidia's revenue was reported to be $8.07 m in FY, 2019
USD

Net income (Q2, 2020)

(13.9m)

EBIT (Q2, 2020)

(13.7m)

Market capitalization (11-Jun-2021)

141.4m

Closing stock price (11-Jun-2021)

2.7

Cash (30-Sept-2020)

79.6m

EV

79.6m
Liquidia's current market capitalization is $141.4 m.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

7.3m2.7m8.1m

Revenue growth, %

(63%)

Cost of goods sold

319.8k121.4k807.2k

Gross profit

6.9m2.6m7.3m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.0m169.7k8.1m

Cost of goods sold

94.3k807.2k

Gross profit

948.5k7.3m

Gross profit Margin, %

91%90%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

3.4m39.5m55.8m

Accounts Receivable

1.6m272.6k

Prepaid Expenses

443.5k219.1k590.3k

Current Assets

5.5m40.0m56.4m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

9.2m47.5m60.8m52.1m39.3m40.1m23.6m79.6m

Accounts Receivable

73.9k81.9k10.5k604.0k945.7k

Prepaid Expenses

227.7k240.9k302.9k323.4k486.5k884.9k750.0k1.1m

Current Assets

9.5m47.8m61.1m53.0m40.7m41.0m24.3m80.6m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(29.2m)(53.1m)(47.6m)

Depreciation and Amortization

931.9k1.5m2.6m

Accounts Payable

1.9m(1.3m)294.5k

Cash From Operating Activities

(24.3m)(31.8m)(48.3m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(33.8m)(43.5m)(13.8m)(19.7m)(33.1m)(14.8m)(28.7m)(43.7m)

Depreciation and Amortization

725.9k1.1m609.0k1.2m2.0m732.0k1.5m2.2m

Accounts Payable

(1.3m)(1.7m)2.9m1.0m1.4m2.2m(749.2k)133.5k

Cash From Operating Activities

(17.2m)(23.5m)(10.1m)(22.3m)(34.2m)(14.4m)(27.5m)(40.1m)
Show all financial metrics

Liquidia Operating Metrics

FY, 2018

Patients Reached

109
Show all operating metrics

Liquidia Revenue Breakdown

Embed Graph

Liquidia revenue breakdown by business segment: 16.2% from GSK Inhaled and 83.8% from Other

Liquidia Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Liquidia Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Liquidia Online and Social Media Presence

Embed Graph

Liquidia News and Updates

United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc. (a subsidiary of Liquidia...

Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder

MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension (P…

Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration

Sandoz Generic Treprostinil Injection now available for both routes of administration, subcutaneous and intravenous Sandoz Generic Treprostinil Injection now available for both routes of administration, subcutaneous and intravenous

Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

MORRISVILLE, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (NDA) for LIQ861 for the treatment of pulmonary arterial hypertension (PAH). The U.S. Food and Drug Administration (FDA) issued a Com…

Liquidia Corporation to Report First Quarter 2021 Financial Results on May 13, 2021

MORRISVILLE, N.C., May 06, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2021 financial results on Thursday, May 13, 2021. The company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss financia…

Liquidia Corporation To Present At The 20th Annual Needham Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the 20th Annual Needham V…
Show more

Liquidia Blogs

Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference

MORRISVILLE, N.C. , May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia , will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare

Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update

Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update Content Import Thu, 05/13/2021 - 07:03 Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update May 13, 2021 This release is a backfill from a News …

Liquidia Frequently Asked Questions

  • When was Liquidia founded?

    Liquidia was founded in 2004.

  • Who are Liquidia key executives?

    Liquidia's key executives are Stephen Bloch, Mike Kaseta and Robert Lippe.

  • How many employees does Liquidia have?

    Liquidia has 64 employees.

  • What is Liquidia revenue?

    Latest Liquidia annual revenue is $8.1 m.

  • What is Liquidia revenue per employee?

    Latest Liquidia revenue per employee is $126.1 k.

  • Who are Liquidia competitors?

    Competitors of Liquidia include JINIS Biopharmaceuticals, EVerZom and Bio-Synectics.

  • Where is Liquidia headquarters?

    Liquidia headquarters is located at 419 Davis Dr, Morrisville.

  • Where are Liquidia offices?

    Liquidia has an office in Morrisville.

  • How many offices does Liquidia have?

    Liquidia has 1 office.